Form D · Biotechnology

Altea Therapeutics Corp

Atlanta, GA · CIK 0001310392

Offering snapshot reported Oct 25, 2010 · SEC filing

Reported sold
$685K
Offering amount: $685K
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 14, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 25, 2010Initial$685,000No comparison8SEC filing
May 13, 2009Initial$3,000,000No comparisonNot reportedSEC filing
Aug 9, 2005PaperNot reportedNo comparisonNot reportedSEC filing
Nov 29, 2004PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-149515

Source: Form D, filed Oct 25, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steven P. Damon Executive
Ruth Devenyns Director
Deborah Eppstein Director
Anthony B. Evnin Director
William R. Good Director
Michael Hatch Executive
Harold Shlevin Executive
Alan Smith Executive
Frank E. Tagliaferri Executive
Paul E. Tierney Director
Eric Tomlinson Director, Executive
Jesse I. Treu Director
Angela Walsh Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
387 Technology Circle Nw Suite 100
Atlanta, GA, 30013